Eli Lilly to Invest $6.5 Billion in Texas Manufacturing Hub for Obesity Pill and Other Pipeline Drugs
Wegovy Trial Data Lifts Novo Nordisk as U.S. Market Challenges Weigh on Growth
Eli Lilly Shares Slide as Obesity Pill Shows Modest Results in Late-Stage Trial
Healthcare’s Wild Week: What UnitedHealth’s Crash and GSK’s Deal Mean for Investors
Trump's Drug Price Order Spooks Markets - Then Sparks a Comeback
Pump Radar
Stock Alerts